Heart failure & cardiomyopathies
Projecting the Benefit of Vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA Trial
Authors' conclusion
A trend towards enhanced efficacy of vericiguat in populations simulated from PARADIGM-HF and DAPA-HF was observed.
Study context
- Population
- VICTORIA participants with high-risk heart failure (HF), subgroups simulating PARADIGM-HF- and DAPA-HF-eligible populations
- Participants
- 5,050 participants
- Comparison
- Vericiguat vs placebo
- Primary endpoint
- HF hospitalization or CV death
Methodological detailssimulated trial-eligible subgroups, unadjusted Cox proportional hazards model
- Simulated trial-eligible subgroups
- Unadjusted Cox proportional hazards model
Primary result
As reported in the abstract
HF hospitalization or CV death, by simulated trial population (subgroup)
Vericiguat vs PlaceboHazard ratio (95% CI)
PARADIGM-HF-eligible: 1982 (39.2%)
0.85(0.72–0.99)
DAPA-HF-eligible: 2543 (50.4%)
0.82(0.71–0.94)
- Overall VICTORIA trial
- HR 0.90
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| HF hospitalization, by simulated trial population (subgroup)Vericiguatvs PlaceboDAPA-HF-eligible | 0.83 (0.73–0.95) | |
| HF hospitalization, by simulated trial population (subgroup)Vericiguatvs PlaceboPARADIGM-HF-eligible (nominal reduction) | 0.86 (0.74–1.01) | |
| 0.512Hazard ratio (log scale) |
Original publication
Projecting the Benefit of Vericiguat in PARADIGM-HF and DAPA-HF populations: Insights from the VICTORIA Trial. ESC Heart Fail. Published 22 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →